Skip to main content

Buy calls| Pfizer| Venkys India| Blue dart Express|

 Pfizer: Buy | CMP: Rs 4,774.50 | Target: Rs 5,280 | Stop Loss: Rs 4,560 | Return: 10 percent

After breaking out of rounding bottom formation, the stock has retraced till its 20-day moving average and showing signs of life again. Prices are trading above all its short term and medium term moving averages ribbon and momentum indicators are trading in a bullish zone. The short term moving averages are developing a positive curve after a phase of mild correction suggests that reversal after retracement can be expected in the counter. There is a formation of higher top and higher bottom on weekly as well as monthly charts. The daily RSI is bouncing back from important support levels indicates that short term up move can be expected in the counter. Traders can accumulate it at the current market price (CMP) and on any dip till Rs 4,650 with the short term perspective.



Venkys India: Buy | CMP: Rs 1,520.05 | Target: Rs 1,760 | Stop Loss: Rs 1,390 | Return: 15 percent

The stock has broken out of a falling trend line resistance and started trading above its major medium term moving averages. The short term moving averages in the weekly time frame has developed a positive curve indicating the initial sign of trend reversal buying. The weekly RSI has started trading in a bullish zone for the first time after April 2018 suggests that momentum is building up in the stock and the short term rally might not be ruled out. On the daily chart, the lower top and lower bottom cycle has reversed indicating the worst is over and bulls are likely to take the charge again. The average directional index (ADX) is trading with a positive slope suggesting the trending move in the stock. Traders can initiate buying positions at CMP and on any dip till Rs 1,490 for the short term gain.

Blue Dart Express: Buy | CMP: Rs 2,289 | Target: Rs 2,564 | Stop Loss: Rs 2,140 | Return: 12 percent

The stock has been consolidating in the trading range since March 2020 and seems to be poised for the fresh breakout. The RSI has bounced back from the important support area and is trading in a bullish zone. Recently, the bullish crossover of short and medium-term moving averages ribbon has been witnessed on daily chart suggesting that bulls are likely to have upper hands in the coming days. Bullish crossover in momentum indicators and volatility breakout in the hourly chart suggests that a decent move can be expected in the counter in short term. Traders can initiate long positions at CMP and can add more once the stock starts trading above Rs 2,320 for short term gain.

Disclaimer:

 SD Solutions advises users to check with certified experts before taking any investment decisions.


*Sources - moneycontrol.com,  Rudra Shares & Stock Brokers Ltd. (SEBI Reg.No.INH100002524) (RA).

 

Comments

Post a Comment

Popular posts from this blog

Ashoka Buildcon share price up 4% on bagging 2 NHAI projects

The share touched its 52-week high Rs 127.90 and 52-week low Rs 37.00 on 23 September, 2019 and 03 April, 2020, respectively. Ashoka Buildcon share price added over 4 percent in early trade on September 8 after the company emerged as the lowest bidder (L-1) for the two NHAI projects. The aggregate quoted value of the projects is Rs 1,390 crore. The company had submitted bids to National Highway Authority of India (NHAI) for the project of four laning of Arra h to Pararia section of NH-319(Old NH-30) in the State of Bihar under Bharatmala pariyojana Phase -1 on EPC Mode (Package-I) and Four laning of Pararia to Mohania section of NH-319(Old NH-30) in Bihar under Bharatmala Pariyojana Phase-I on EPC Mode (Package II). At 09:23 hrs Ashoka Buildcon was quoting at Rs 70.60, up Rs 2.40, or 3.52 percent on the BSE. The share touched its 52-week high Rs 127.90 and 52-week low Rs 37.00 on 23 September, 2019 and 03 April, 2020, respectively. Currently, it is trading 44.8 percen...
Post a Comment
Read more

Reliance Jio Q3 results: Profit grows to Rs 3,489 crore; ARPU rises to Rs 151

  The average revenue per user (ARPU) during the quarter came at Rs 151 per subscriber per month as against Rs 145 per subscriber per month in the September quarter. Reliance Jio, the telecommunications arm of Jio Platforms, on January 22 posted a net profit of Rs 3,489 crore for the quarter ended December 31, 2020. The profit was higher than the street expectations as analysts in a CNBC-TV18 poll had estimated the number at Rs 3,200 crore. Jio's net profit grew 15.5 percent QoQ as in the September quarter of FY21, its profit was Rs 3,020 crore. The average revenue per user (ARPU) during the quarter came at Rs 151 per subscriber per month as against Rs 145 per subscriber per month in the September quarter. A CNBC-TV18 poll had estimated ARPU at Rs 148.2. Revenue, including access revenues for the quarter, was Rs 22,858 crore ($3.1 billion), up 5.3 percent QoQ. A CNBC-TV18 poll had estimated revenue to the tune of Rs 18,165 crore. EBITDA for the quarter stood at Rs 8,483 crore ...
Post a Comment
Read more

US investors' rights law firm announces probe against HDFC Bank

  The investigation is reportedly resulting from allegations that HDFC Bank may have issued materially misleading business information to the investing public.   American Law firm, Rosen Law, has announced an investigation of potential securities claims on behalf of shareholders of HDFC Bank. The firm is also preparing for a class action suit on behalf of bank’s shareholders. The investigation is reportedly resulting from allegations that HDFC Bank may have issued materially misleading business information to the investing public. Rosen Law, on its website, asked investors to provide their details if they have purchased HDFC Bank Limited securities and would like to receive information about the investigation concerning the class action to recover the investor losses in HDFC Bank Limited securities. “A representative of The Rosen Law Firm will contact you at no cost to you and provide you detailed information concerning the proposed class action to rec...
Post a Comment
Read more